In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals in Depth: September 2009

Executive Summary

Boston Scientific's lawsuit settlement with Cordis and concurrent IP license topped the alliance list at $716 million. Even without counting the two monster IPOs by Talecris ($550 million) and China's Sinopharm ($1.1 billion), total money raised in biopharma still increased in September by 26%. Device financing decreased by over $100 million to $266 million.

You may also be interested in...



QUOTED. 22 October. Robert Ford.

Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.

China Regulatory Express: Biosecurity Law, Export Controls And The Life Science Sector

With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.

Mediocre Vaccine Could Make Pandemic Worse, Non-Profit Group Tells US FDA

Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.

Topics

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel